Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance

CONCLUSIONS: Using pegylated liposomal doxorubicin as part of a platinum doublet preceding maintenance PARPi for platinum-sensitive recurrence does not seem to hasten PARPi resistance or platinum resistance compared to OPDs. Although there was a non-significant trend towards increased OS among patients who received a platinum doublet other than CD prior to PARPi, the OS from PARPi start was similar between groups. Given the retrospective nature of this study and small study population, further research is needed to evaluate if the choice of platinum doublet preceding PARPi maintenance impacts PARPi resistance, platinum resistance and survival.PMID:38262238 | DOI:10.1016/j.ygyno.2023.12.008

Source: Gynecologic Oncology - January 23, 2024 Category: Cancer & Oncology Authors: Monica D Levine Heather Wang Bhargavi Sriram Ambar Khan Leigha Senter Eric M McLaughlin Kristin L Bixel Laura M Chambers David E Cohn Larry J Copeland Casey M Cosgrove Christa I Nagel David M O'Malley Floor J Backes Source Type: research